A research found that type I and type II IFNs are able to promote PD-L1 expression in patient-derived glioma cells in a synergistic manner, while type I IFNs can induce strong expression of PD-L1 with IFN-γ, which undoubtedly has a detrimental effect on tumor treatment (123). Here, CD274 is linked to glioma.